Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to ...
Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.
We recently published an article titled Why These 10 Dividend Stocks Are Declining? In this article, we are going to take a ...
Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...
Palantir is gaining significant traction in the tech world with its AI-driven services, experiencing a dramatic stock ...
Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...
Stocks remain jittery on a mix of inflation worry coupled with concern over how Trump’s plan for tariffs could affect the U.S. economy ...
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
Robert F. Kennedy Jr.'s nomination for US health secretary advances with crucial Republican support, despite controversy over ...
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results